Menu
FocalTherics™ - Investor Relations
About FocalTherics
A recognized global leader in Robotic Focal Therapy, FocalTherics (NASDAQ: FOCL) develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life. FocalTherics is committed to expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and global market development initiatives. For more information about FocalTherics, visit FocalTherics.com.
Minimum 15 minutes delayed.
Source: LSEG
Sept. 26th 8:00 AM ET/PT - Lifetime Network
Focal One On Health Uncensored With Dr. Drew
Watch Focal One’s first national TV segment that aired on Sept. 26th at 8:00 AM (ET/PT) on the Lifetime Network as a part of Health Uncensored with Dr. Drew. Disclaimer: Nothing in this video is intended to provide specific medical advice or to take the place of written law or regulations.
MARCH 18, 2026
Investor Presentation
Positioned for Growth
The Global Leader in Innovation and Delivery of Advanced Ultrasound Technologies for both the Diagnosis and Treatment of Diseases.
Financial Results
EDAP Announces Preliminary Record Fourth Quarter Focal One® System Sales and Record U.S. Procedures
AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar year 2024..
AUSTIN, Texas, January 13, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced preliminary record Focal One System sales for the fourth quarter of calendar year 2024..